Given COVID-19, is there a good hypofractionated regimen for postmastectomy radiation for locally advanced breast cancer?  

In light of COVID-19, we offer 2.66 x 16 PMRT with comprehensive RNI. This regimen is under study in ALLIANCE A221505, commonly known as RT-CHARM. Primary endpoint is reconstruction complications at 2 years. We discuss with reconstructed patients (most all will take if offered). Routinely given to u...

I break these cases down into 3 groups of locally advanced: 1. Intact breast 2. Mastectomy without reconstruction 3. Mastectomy with reconstruction For #1 and #2, I am routinely offering hypofractionation to the breast/chest wall and RNI to 40 Gy/15 fractions. For #3, I agree with @Neil Taunk&n...